Moreover, an exploratory subgroup analysis was conducted on the OAK study ( 20 ), Considering patients who have or have not previously had asymptomatic, treated brain metastases, anti-PD-L1 atezolizumab showed a favorable safety profile, and ezolizumab compared to docetaxel showed a trend in favor of a longer OS (16 versus 11.9 months).
← all excerpts
Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases.
1
—
—